Biopharma | December 08, 2025
Halozyme wins German injunction blocking Merck’s Keytruda distribution
While Merck can appeal, Halozyme said it expects the order to hold
While Merck can appeal, Halozyme said it expects the order to hold
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules
The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands
The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease
Several technologies for hemoglobinopathies are being transferred to commercial partners
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
IND application for EB-003 expected in early 2026
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
Subscribe To Our Newsletter & Stay Updated
